malaria vaccines

Development of malaria drugs and vaccines

harminka — Thu, 09 Oct 2008 07:14:15 -0500

Scientists have deciphered the complete genetic sequence of the parasite Plasmodium vivax, the leading cause of relapsing malaria, and compared it with the genomes of other species of malaria parasites.

Searching for volunteers to test new vaccines

seher — Fri, 07 Mar 2008 09:28:52 -0600

Seattle Biomedical Research Institute finally has moved into clinical trials with a whole organism genetically attenuated malaria vaccine. The largest independent, non-profit organization in the United States is in need of extra volunteers to be bitten by a malaria-carrying mosquito in order to test vaccines.

Scientists need volunteers to try malaria vaccines

seher — Thu, 06 Mar 2008 11:32:27 -0600

The Seattle Biomedical Research Institute will pay volunteers as much as $4,000 to be bitten by mosquitoes infected with malaria. Malaria is one of the most common infectious diseases and an enormous public health problem.

New test for malaria protection

harminka — Mon, 03 Mar 2008 12:18:14 -0600

ETH Zurich professor Peter Seeberger has been working on a sugar-based malaria vaccine for years. The new test takes him one important step closer to his goal. The malaria pathogen plasmodium falciparum carries poisonous sugar molecules – called GPIs for short – on its surface that are able to be individually identified.

Malaria vaccine trials begin using 'chimpanzee virus'

seher — Sat, 02 Feb 2008 04:20:41 -0600

Trials are underway for a new vaccine to combat the most deadly form of malaria. For the first time ever, researchers will use a virus found in chimpanzees to boost the efficacy of the vaccine. The trials will take place at the University of Oxford's Jenner Institute, led by its Director, Professor Adrian Hill, and are funded by the Wellcome Trust.

Evidence vaccine against malaria will reduce disease

harminka — Mon, 24 Dec 2007 07:57:35 -0600

Researchers at the Case Western Reserve University School of Medicine's Center for Global Health & Diseases published data potentially having a strong effect on the three billion people exposed to malaria every year.

Malaria vaccine candidate has promising safety profile in infants

harminka — Thu, 18 Oct 2007 08:23:55 -0500

The first study to test GlaxoSmithKline's (GSK) investigational RTS,S/AS02 malaria vaccine in African infants serves as the first proof of concept in this population that the vaccine has a promising safety and tolerability profile and reduces malaria parasite infection and clinical illness due to malaria, according to a paper published today online in The Lancet.

New rapid identification and development of malaria vaccines

harminka — Wed, 25 Jul 2007 05:03:23 -0500

Malaria is the world’s most frequent parasitic disease, affecting more than 100 countries in the tropical zones, mostly in Africa, and 40% of the world population, with more than a million deatths per year. As a consequence countries affected by malaria also tend to be economically disadvantaged.

Vaccine hope for malaria

harminka — Thu, 24 May 2007 11:21:08 -0500

One person dies of it every 30 seconds, it rivals HIV and tuberculosis as the world's most deadly infection and the vast majority of its victims are under five years old. Now, just over 100 years since Britain's Sir Ronald Ross was awarded the Nobel Prize for finally proving that malaria is transmitted by mosquitoes, researchers at The University of Nottingham believe they have made a significant breakthrough in the search for an effective vaccine.

Australian Experts Aim to Find Best Ways to Fight Malaria in Pacific Nations

Dinka — Fri, 18 May 2007 12:43:29 -0500

A team of Australian malaria experts has been meeting in Canberra to find the most efficient ways to combat the disease in the South Pacific. Canberra has just announced a new multi-million dollar aid package to help efforts in the Solomon Islands, Vanuatu and Papua New Guinea.

New partnership will develop novel malaria vaccine

harminka — Thu, 14 Dec 2006 16:12:23 -0600